. Author manuscript; available in PMC: 2019 Sep 1.

Published in final edited form as: Cancer Discov. 2018 Jul 16;8(9):1156–1175. doi: 10.1158/2159-8290.CD-17-1033

Table 2.

Co-inhibition of PD-L1 and CD38 produces a favorable anti-tumor microenvironment.

Infiltrating immune cells in LLC-JSP-bearing tumors	Combination therapy of anti-PD-L1 and anti-CD38				Combination therapy of anti-PD-L1 and Rhein
Infiltrating immune cells in LLC-JSP-bearing tumors	Control	anti-PD-L1	anti-CD38	Combination	Control	anti-PD-L1	Rhein	Combination
% of CD8⁺ T cells	5.05 ± 0.49	4.70 ± 0.32	9.15 ± 1.19	20.80 ± 1.21	4.99 ± 0.55	4.78 ± 0.39	7.13 ± 0.79	23.15 ± 0.82
% of CD44^highCD62L^low in CD8⁺ T cells	50.90 ± 1.90	46.10 ± 1.18	64.48 ± 3.29	75.10 ± 1.04	50.68 ± 1.59	41.55 ± 3.97	55.84 ± 2.98	70.36 ± 1.07
% of PD-1⁺TIM3⁺ in CD8⁺ T cells	30.43 ± 2.17	38.53 ± 2.98	23.84 ± 1.67	10.12 ± 0.86	30.40 ± 1.44	40.03 ± 4.39	22.66 ± 1.96	13.68 ± 1.47
% of CD4⁺ICOS⁺ T cells	4.27 ± 0.46	6.26 ± 0.53	6.70 ± 0.65	9.20 ± 0.58	4.44 ± 0.47	6.72 ± 0.31	5.45 ± 0.50	8.78 ± 0.70
% of Tregs in CD4⁺ T cells	10.63 ± 0.45	13.90 ± 0.54	5.13 ± 0.30	2.83 ± 0.47	10.75 ± 0.56	15.25 ± 0.97	8.47 ± 0.72	4.77 ± 0.63
% of MDCSs in CD45⁺ cells	24.38 ± 1.98	30.53 ± 1.01	11.50 ± 1.40	5.17 ± 1.14	25.13 ± 2.10	30.78 ± 1.18	14.95 ± 1.94	8.66 ± 1.52